Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation??

Author： Caserta Donatella   Lisi Franco   Marci Roberto   Ciardo Francesca   Fazi Alessandra   Lisi Roberta   Moscarini Massimo  

Publisher： Informa Healthcare

ISSN： 1473-0766

Source： Gynecological Endocrinology, Vol.27, Iss.11, 2011-11, pp. : 862-866

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol

By Griesinger G.   Schultze-Mosgau A.   Dafopoulos K.   Schroeder A.   Schroer A.   von Otte S.   Hornung D.   Diedrich K.   Felberbaum R.  

Human Reproduction, Vol. 20, Iss. 5, 2005-05 ,pp. : 1200-1206

Oxford University Press

Access to resources Recommend Favorite

Intravenous albumin does not prevent moderate‐severe ovarian hyperstimulation syndrome in high‐risk IVF patients: a randomized controlled study

By Bellver José   Muñoz Elkin A.   Ballesteros Agustín   Soares Sérgio Reis   Bosch Ernesto   Simón Carlos   Pellicer Antonio   Remohí José  

Human Reproduction, Vol. 18, Iss. 11, 2003-11 ,pp. : 2283-2288

Oxford University Press

Access to resources Recommend Favorite

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).

By ganirelix dose-finding study group The  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3023-3031

Oxford University Press

Access to resources Recommend Favorite

Case report. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)

By Itskovitz-Eldor J  

Human Reproduction, Vol. 13, Iss. 2, 1998-02 ,pp. : 294-295

Oxford University Press

Access to resources Recommend Favorite

Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone

By Messinis IE  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2415-2420

Oxford University Press

Access to resources Recommend Favorite